FY2026 EPS Forecast for Palisade Bio Reduced by Analyst

Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Stock analysts at HC Wainwright reduced their FY2026 earnings estimates for Palisade Bio in a research note issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.24) per share for the year, down from their previous estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.33) EPS.

A number of other brokerages have also recently issued reports on PALI. Wall Street Zen cut Palisade Bio from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. Finally, Raymond James Financial began coverage on Palisade Bio in a research note on Thursday, October 8th. They issued an “outperform” rating and a $6.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Palisade Bio has an average rating of “Buy” and a consensus price target of $9.00.

View Our Latest Report on PALI

Palisade Bio Trading Down 1.8%

Shares of NASDAQ PALI opened at $1.12 on Friday. The company has a market cap of $200.79 million, a price-to-earnings ratio of -2.33 and a beta of 1.61. Palisade Bio has a 12 month low of $1.08 and a 12 month high of $2.85. The stock has a 50-day moving average price of $1.48 and a two-hundred day moving average price of $1.82.

Palisade Bio (NASDAQ:PALI – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01).

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of Palisade Bio by 19.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company’s stock valued at $117,000 after buying an additional 13,110 shares during the last quarter. Legal & General Group Plc purchased a new stake in Palisade Bio in the 2nd quarter valued at $30,000. CTC Alternative Strategies Ltd. purchased a new stake in Palisade Bio in the 1st quarter valued at $31,000. WINTON GROUP Ltd lifted its stake in Palisade Bio by 180.2% during the 2nd quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock valued at $67,000 after acquiring an additional 20,727 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Palisade Bio during the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Company Profile

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Featured Stories

Earnings History and Estimates for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.